Abstract Valproic acid (VPA) as a broad-spectrum inhibitor of histone deacetylase, has been used in cancer therapy. Recently, the combination of VPA with other anticancer agents has been considered as a useful and necessary strategy to inhibit tumor growth and progression. The coumarin derivates from natural plants have been shown to be the promising natural anticancer agents. However, no literature is available on the anticancer effects of the combination of VPA and coumarin-3-carboxylic acid (HCCA). Here we show that this combination significantly increases inhibitory effects against the proliferation and migration in highly-metastatic lung cancer cells by inducing apoptosis and cell cycle arrest as well as regulating related protein expressions. Our results indicate that this combination of VPA with HCCA not only enhances the protein levels of Bax, cytosolic cytochrome c, caspase-3 and PARP-1 but also reduces the protein expressions of Bcl-2, cyclin D1 and NF-jB as well as inhibits the phosphorylation and expressions of Akt, EGFR, VEGFR2 and c-Met in the cancer cells. Our results suggest that the combination of VPA with HCCA suppresses the proliferation and migration of lung cancer cells via EGFR/VEGFR2/c-Met-Akt-NFjB signaling pathways; this combination may have a wide therapeutic and/or adjuvant therapeutic application in the treatment of lung cancer.
Introduction
Lung adenocarcinoma is the leading cause of cancerrelated deaths in the world (Jemal et al. 2008 Siegel et al. 2011 Siegel et al. , 2012 . It is estimated that there will be more than 226,000 new cases and about 160,000 deaths from lung & bronchus cancer in the US in 2012 (Siegel et al. 2012) . Despite recent advances in diagnosis and treatment, overall 5-year survival of lung cancer patients is only about 15 %. The patients with advanced disease have a median survival of approximately 10 months when treated with standard platinum-based therapy. Hence, there is an imminent need for better therapies and/or anticancer agents for lung cancer. Valproic acid (VPA, 2-propylpentanoic acid) is an established drug in the long-term therapy of epilepsy. During the past years, it has become evident that valproic acid is also associated with anticancer activity. Valproic acid not only suppressed some tumor growth and metastasis, but also induced tumor differentiation in vitro and in vivo (Blaheta and Cinatl 2002) . Valproic acid inhibited the in vitro and in vivo cancer cell growth of melanoma (Landreville et al. 2012) , urinary bladder cancer (Byun et al. 2009; Ozawa et al. 2010) , breast cancer (Munster et al. 2009 ), and prostate cancer (Chou et al. 2011) . Recently, the combination of valproic acid with other anticancer agents has been considered as a useful and necessary strategy to inhibit tumor growth and progression (Byun et al. 2009; Munster et al. 2009; Ozawa et al. 2010; Chou et al. 2011) . The coumarin derivates from natural plants have been shown to be the promising natural anticancer agents. There are some reports showing that some coumarin derivates have enhanced effects with anticancer drugs against the cell growth of gastric cancer (Kim et al. 2012) , bladder cancer (Rassouli et al. 2011) , and leukemia (Lin et al. 2009 ). However, no literature is available on the anticancer effects of the combination of valproic acid and coumarin-3-carboxylic acid (HCCA) whose chemical structure is shown in Fig. 1a . In order to understand the effects of combination of VPA and HCCA on proliferation and migration of highly-metastatic lung cancer cells and its molecular mechanisms of action, we investigated the effects of combination of VPA and HCCA on apoptosis, cell cycle distribution, and migration as well as the related receptor-mediated signaling pathways in the cancer cells.
Materials and methods

Chemicals and antibodies
The primary antibodies to mouse Bcl-2, Bax, caspase-3, PARP-1, cytochrome c, cyclic D1, nuclear factor (NF-jB p-65), Akt, pAkt, and b-actin were purchased from Cell Signaling Technology Inc. (Beverley, MA, USA). The primary antibodies to mouse pVEGFR2, VEGFR2, pEGFR, EGFR, p-c-Met, and c-Met were purchased from Santa Cruz Technology Inc. (Santa Cruz, CA, USA). Fibronectin and Boyden chambers were purchased from BD Inc. (BD Biosciences, San Jose, CA, USA) and Corning Inc. (Corning, NY, USA), respectively. DMEM, penicillin, streptomycin, fetal bovine serum (FBS), trypsin/EDTA, propidium iodide, Ly294002 (Ly), Bay 11-7082 (Bay), 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), sodium valproate (VPA), coumarin-3-carboxylic acid (HCCA), and all other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Cell culture and in vitro proliferation assay
The highly-metastatic Lewis lung cancer (LLC) cell line, the normal mouse fibroblast NIH3T3, and the normal human umbilical endothelial vein cells (EA.hy926) were obtained from the American Type Culture Collection. The cell lines of LLC, NIH3T3 and EA.hy926 were cultured in DMEM containing 10 % heat-inactivated fetal bovine serum (FBS), glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 lg/ml) at 37°C in a humidified incubator with 95 % air/5 % CO 2 atmosphere. The in vitro assay was performed according to our published methods (Liu Fig. 1 Effects of combination of sodium valproate (VPA) and coumarin-3-carboxylic acid (HCCA) on proliferation and induction of apoptosis and cell cycle arrest in LLC cells as well as the growth of NIH3T3 and EA.hy926 cells. a Chemical structure of HCCA. b Inhibition of the LLC cell growth by combination of VPA and HCCA. c Effect on NIH3T3 cell growth. d Effect on EA.hy926 cell growth. The cells were treated for 48 and 72 h with the indicated concentrations of VPA/V and HCCA/C (V0.5/0.5 mM, V1/1 mM, C64/0.064 mM, C125/ 0.125 mM), Ly (0.0125 mM), and Bay (0.0025 mM). The cells in control group (0) were treated with DMSO. The relative cell growth (%) was determined by the MTT assay. Ly294002 (Ly) and Bay are the inhibitors of PI3K/Akt and NF-jB, respectively. e Induction of apoptosis (cells in Sub-G 1 phase) and cell cycle arrest in LLC cells by combination of VPA and HCCA was analyzed by flow cytometry. The cells were treated for 48 h with VPA (0.5 mM), HCCA (0.064 mM), Bay (0.0025 mM) and Ly294002 (0.0125 mM) as the positive control, and combination of VPA (0.5 mM) and HCCA (0.064 mM). The data are presented as the mean ± SD (Bar) (n = 6). The figures are the representative of 3 similar experiments performed. Values with different letters (a-d) differ significantly (P \ 0.05). c/s represents the significant enhanced effects (P \ 0.05) compared with VPA or HCCA alone. *P \ 0.05 Luan et al. 2010; Zhang et al. 2000; Jiang et al. 2010) . Cells were plated in 96-well plates (BectonDickinson, Franklin Lakes, NJ, USA) at 2 9 10 3 per well and incubated overnight to allow attachment. The cells in control group were treated with DMSO [0.1 % (v/v), final concentration]. The cells were respectively incubated in DMEM medium supplemented with 10 % FBS containing different concentrations of sodium valproate (VPA, 0.5-1 mM), coumarin-3-carboxylic acid (HCCA, 0.064-0.125 mM), or in combination of VPA and HCCA, or Ly294002 (Ly, 0.0125 mM), Bay (0.0025 mM). Ly and Bay are the inhibitors of PI3K/ Akt, and NF-jB, respectively. After 48 and 72 h of treatment, 20 lL of MTT (5 mg/ml) was added to each well of cells, and the plate was incubated for 3 h at 37°C. One hundred and fifty microliters DMSO were added to each well to lyse the cells. Absorbance was measured at a wavelength of 570 nm and a reference wavelength of 630 nm using a Synergy H4 Hybrid Multi-Mode Microplate Reader (Bio-Tek, Instruments, Inc., Winooski, VT, USA). Absorbance values in each test group were normalized to the values of the control group treated with 0.1 % (v/v) DMSO to determine the relative cell growth (%) of LLC, NIH3T3 and EA.hy926 cell lines. Here the absorbance values are designated as the relative cell growth (%) of these cell lines. The relative cell growth (%) of these cell lines in the control group was designated as 100 %. Each experiment was performed in triplicate and repeated at least three times.
Flow cytometry for cell cycle analysis and apoptosis These were done according to our published methods (Wang et al. 2009; Yu et al. 2009; Zhang et al. 2000 Zhang et al. , 2012a . In brief, LLC cells were treated for 48 h with sodium valproate (VPA, 0.5 mM), coumarin-3-carboxylic acid (HCCA, 0.064 mM), or in combination of VPA (0.5 mM) and HCCA (0.064 mM). The cells in control group were treated with DMSO [0.1 % (v/v), final concentration]. The treated cells were detached in PBS/ 2 mM EDTA, centrifuged at 300xg for 5 min, and then gently resuspended in 250 lL of hypotonic fluorochrome solution (PBS, 50 lg propidium iodide, 0.1 % sodium citrate, and 0.1 % Triton X-100) with RNase A (100 units/ml). The function of the fluorochrome solution is to stain cell nuclei. The DNA content was analyzed by flow cytometry FACS Vantage SE (Becton-Dickinson, San Jose, CA, USA). Twenty-thousand events were analyzed per sample and the cell cycle distribution and apoptosis were determined based on DNA content and the Sub-G 1 cell population, respectively.
In vitro migration assay
Tumor cell migration was measured by examining cell migration through fibronectin-coated polycarbonate filters, using modified transwell chambers. In brief, LLC cells (5 9 10 4 ) were seeded onto the upper chamber in 200 lL of serum-free medium containing different concentrations of sodium valproate (VPA, 0.125-0.5 mM), coumarin-3-carboxylic acid (HCCA, 0.008-0.016 mM), or in combination of VPA and HCCA; the lower compartment was filled with 0.66 mL of DMEM medium supplemented with 10 % of FBS (as a chemoattractant). The cells in control group were treated with DMSO (0.1 %, final concentration). After incubation for 6 h at 37°C, the cells that migrated to the lower surface of the filter were fixed and stained using propidium iodide. The cells on the upper side of the filter were removed using a rubber scraper. The migrated cells on the underside of the filter were counted and recorded for images under a fluorescent microscope (Nikon, TE2000-U, Japan). Experiments were performed in triplicate.
Western blot analysis
This was performed according to our published methods with some modifications (Wang et al. 2009; Yu et al. 2009; Zhang et al. 2009 Zhang et al. , 2012a Jiang et al. 2010) . In brief, LLC cells were treated with different concentrations of sodium valproate (VPA, 0.5-1 mM), coumarin-3-carboxylic acid (HCCA, 0.064-0.125 mM), or in combination of VPA and HCCA, or Ly294002 (Ly, 0.0125 mM), Bay (0.0025 mM). The cells in control group were treated with DMSO [0.1 % (v/v), final concentration]. The treated cells were collected either at 30 min for detection of phosphorylation ratios of pVEGFR2/pVEGFR2, pEGFR/EGFR, p-c-Met/c-Met, and pAkt/Akt, or at 48 h for detection of protein expressions of Bcl-2, Bax, procaspase/caspase-3, PARP-1, cyclin D1, NF-jB (p65), and cytosolic cytochrome c. The cells were harvested and washed with PBS. Whole cellular proteins were extracted and cytosolic fractions were prepared following the procedure described by the manufacturer (Beyotime Institute of Biotechnology, Haimen, Jiangsu, China). The protein concentration of the extracts was determined using the Bradford method. Equal amounts of cell extracts were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and probed with the primary antibodies to the detected proteins mentioned above, and then horseradish peroxidase-conjugated secondary antibodies, respectively. Anti-b-actin antibody was used as a loading control. Detection was done using an enhanced chemiluminescence system (GE Healthcare Life Sciences, Piscataway, NJ, USA).
Statistical analysis
The data are expressed as mean ± standard deviation (SD) and analyzed by the SPSS 13.0 software to evaluate the statistical difference. Statistical analysis was done using the ANOVA and Bonferroni test. Values between different treatment groups at different times were compared. The rate (%) of cell viability and mean protein levels are shown for each group. For all tests, P values \0.05 were considered statistically significant. All statistical tests were two-sided.
Results and discussion
Combination of sodium valproate (VPA) and coumarin-3-carboxylic acid (HCCA) enhances the proliferation inhibition and induction of apoptosis and cell cycle arrest in LLC cells
We first investigated the effects of combination of sodium valproate (VPA) and coumarin-3-carboxylic acid (HCCA) on the in vitro proliferation of highlymetastatic LLC. The MTT assay confirmed that the combination of HCCA and VPA significantly increased the inhibition of LLC cell growth after the cells were treated with VPA (0.5-1 mM) and HCCA (0.064-0.125 mM) for 48 and 72 h, respectively (Fig. 1b) . In the same concentrations, the combination of HCCA and VPA did not show significant inhibition of the growth of the normal mouse fibroblast NIH3T3 (Fig. 1c) and the normal human umbilical endothelial vein cells (EA.hy926) (Fig. 1d) . However, the inhibitor of PI3K/Akt (Ly294002, 0.0125 mM) and NF-jB (Bay, 0.0025 mM) significantly inhibited the growth of LLC (Fig. 1b) and NIH3T3 cells (Fig. 1c) . The inhibitor of NF-jB (Bay, 0.0025 mM) rather than the inhibitor of PI3K/Akt (Ly294002, 0.0125 mM) exhibited significant inhibition of EA.hy926 cell growth (Fig. 1d) . Furthermore, the FACS analysis showed that VPA (0.5 mM) and HCCA (0.064 mM) induced apoptosis and cell cycle arrest at G 1 phase (in the case of VPA treatment) and G 2 phase (in the case of HCCA treatment) in LLC cells, respectively, after the cells were treated for 48 h. The apoptotic ratio of LLC cells was 12.64 % in the treatment by combination of VPA and HCCA while the apoptotic ratios of LLC cells were 6.31 and 5.19 %, respectively, in the individual treatment by VPA and HCCA (Fig. 1e) . The enhancement of the apoptotic ratio of LLC cells by combination of VPA and HCCA could greatly contribute to the additive effect of combination of VPA and HCCA on the proliferation inhibition of LLC cells, as compared with the influence of individual VPA and HCCA (Fig. 1b) .
Combination of VPA and HCCA enhances the migration inhibition in LLC cells
The presence of metastasis is the main cause of morbidity and mortality in millions of patients with cancer. During the complicated process of metastasis, the migration of cancer cells is the most important step. Clearly, an agent which could efficiently inhibit the growth and migration of cancer cells would be a hopeful candidate to suppress cancer progression and metastasis and thus could reduce mortality. Therefore, we examined the effects of combination of VPA and HCCA on the migration in LLC cells. The migration assay indicated that VPA (0.125-0.5 mM) and HCCA (0.008-0.016 mM) significantly and dose-dependently suppressed the migration of LLC cells after the cells were treated for 6 h with VPA and HCCA, which the combination of VPA and HCCA enhanced the migration inhibition in LLC cells (Fig. 2a, b) . The relative migration rate was reduced from 70 to 37 % as the concentrations of VPA were increased from 0.125 to 0.5 mM in the presence of 0.008 and 0.016 mM of HCCA. However, the threshold concentration above which the inhibition of cell migration is not improved could be about 0.5 mM for VPA and 0.016 mM for HCCA. It seems that the increase in the concentrations of either VPA or HCCA in the threshold concentrations can not greatly enhance the suppression of LLC cell migration although the VPA concentrations in this study are less than those already reported for inhibition of cell migration in breast cancer (Li et al. 2012; Zhang et al. 2012a, b) and prostate cancer (Zhang et al. 2011; Wedel et al. 2011; Hudak et al. 2012 ) by VPA treatment (0.8-3.2 mM).
Combination of VPA and HCCA enhances the down-regulation of the protein levels of Bcl-2 and cyclin D1 and increased the up-regulation of the protein levels of Bax, cytosolic cytochrome c, caspase-3, and PARP-1 in LLC cells
To understand the molecular mechanisms of action of the combination of VPA and HCCA on the proliferation and induction of apoptosis and cell cycle arrest in LLC cells, we studied the effects of the combination of VPA and HCCA on the related protein expressions. Our results showed that VPA (0.5-1 mM) and HCCA (0.064-0.125 mM) significantly reduced the ratios of Bcl-2/Bax proteins (Fig. 3a) (Fig. 3a) . Furthermore, VPA (0.5-1 mM) and HCCA (0.64-0.125 mM) up-regulated the expression of cytosolic cytochrome c (Fig. 3b) , caspase-3 (Fig. 3c) , and the cleavage of poly(ADP-ribose) polymerase-1 (PARP-1) (Fig. 3d) in LLC cells. The combination of VPA and HCCA also enhanced the up-regulation of the normalized with respect to b-actin and was expressed as relative optical density (OD). The OD value of the band shown as mean ± SD is relative to that of the control (0, the DMSO vehicle) designated as 100 %. Ly is the inhibitor of PI3K/Akt. For one experiment, 3 assays were carried out and only one set of gels is shown. Values with different letters (a-f) differ significantly (P \ 0.05). e/s represents the significant enhanced effects (P \ 0.05) compared with VPA or HCCA alone Cytotechnology (2013) 65:597-608 603 expression of these proteins in LLC cells (Fig. 3b, c, d) . Moreover, VPA (0.5-1 mM) and HCCA (0.064-0.125 mM) significantly reduced the cyclin D1 protein expression (Fig. 3e) in LLC cells. The combination of VPA and HCCA enhanced the down-regulation of the expression of these proteins in LLC cells (Fig. 3e) . In addition, the inhibitor of PI3K/Akt (Ly) showed the significant suppression of the expressions of the proteins Bcl-2, and cyclin D1 and increased the protein levels of Bax, cytosolic cytochrome c, caspase-3, and the cleavage of PARP-1 in LLC cells (Fig. 3) . One of the main regulatory steps of apoptotic cell death is controlled by the ratio of antiapoptotic and proapoptotic members of the Bcl-2 family of proteins, which determines the susceptibility to apoptosis. Bax, a proapoptotic factor of the Bcl-2 family, is found in monomeric form in the cytosol or is loosely attached to the membranes under normal conditions. Following a death stimulus, cytosolic and monomeric Bax translocates to the mitochondria where it becomes an integral membrane protein and cross-linkable as a homodimer allowing for the release of factors from the mitochondria, such as cytochrome c, to propagate the apoptotic pathway (Oltvai et al. 1993 ). Bcl-2 and its related proteins control the release of cytochrome c from the mitochondria (Reed 1997) . Hallmarks of the apoptotic process include the activation of cysteine proteases, which represent both initiators and executors of cell death. In the cytosol, cytochrome c activates caspase-9, which in turn activates the effector caspases such as caspase-3 and caspase-7 (Stennicke and Salvesen 2000) . In the present study, we observed that the combination of VPA and HCCA significantly enhanced the down-regulation of the antiapoptotic Bcl-2 level and up-regulation of proapoptotic Bax level, leading to reduction of Bcl-2/Bax ratio (Fig. 3a) . Furthermore, the combination of VPA and HCCA significantly enhanced the release of cytocrome c from the mitochondria (Fig. 3b) and subsequently increased caspase-3 activity (Fig. 3c) . Caspase-3 is synthesized as a 35-kDa inactive precursor (procaspase-3), which is proteolytically cleaved to produce a mature enzyme composed of 17-kDa fragments. As shown in Fig. 3C , caspase-3 in cleaved form was enhanced with either the increase in the concentrations of VPA and HCCA, or the combination treatment of VPA and HCCA. In addition, we observed the up-regulation of cleavage of PARP-1, the substrate of caspase-3, in LLC cells treated with the combination of VPA and HCCA (Fig. 3d) . Moreover, our results also indicated that the combination of VPA and HCCA significantly enhanced the down-regulation of cyclin D1 protein expression in LLC cells (Fig. 3e) .
Taken together, all these results show that the combination of VPA and HCCA significantly enhanced the proliferation suppression of LLC cells and the induction of apoptosis and cell cycle arrest by reducing Bcl-2/Bax ratio and activating the mitochondrial and caspase-3 pathway as well as reducing the protein level of cyclin D1, the cell cycle regulator in LLC cells.
Combination of VPA and HCCA enhances the down-regulation of the receptor phosphorylation and protein expression of EGFR, VEGFR2, and c-Met in LLC cells
The activated receptors such as EGFR, VEGFR2, and c-Met play very important roles in the proliferation and migration of cancer cells including lung cancer cells (Morelli et al. 2006; Kim et al. 2008a, b; Puri and Salgia 2008; Naumov et al. 2009; Colon et al. 2011; Zhang et al. 2012a, b) . In order to clarify the VPA-and HCCA-targeted receptors in LLC cells, we studied the effects of VPA and HCCA on the related receptor phosphorylation and expression in LLC cells. We have confirmed that the combination of VPA and HCCA significantly enhanced the inhibition of the phosphorylation and expression of EGFR (Fig. 4a) , VEGFR2 (Fig. 4b) , and c-Met (Fig. 4c) in LLC cells. In addition, the inhibitor of PI3K/Akt (Ly) also showed inhibitory effects on the phosphorylation and expression of these receptors (Fig. 4) (Fig. 5a ) and the NF-jB (p65) expression (Fig. 5b ) in LLC cells. In addition, the inhibitors of PI3K/Akt (Ly) and NF-jB (Bay) also displayed a significant suppression of the phosphorylation and protein expression of Akt and the NF-jB (p65) expression in LLC cells, respectively (Fig. 5a,  b) . Akt is a cytosolic signal transduction protein kinase that plays an important role in cell survival pathways (West et al. 2002) . Induction of Akt activity is primarily dependent on the PI3K pathway. Akt can be activated by many forms of cellular stress, such as those observed under treatment with anticancer agents (West et al. 2002) . Once activation, Akt controls cellular functions such as apoptosis, cell cycle, gene transcription, and protein synthesis through the phosphorylation of downstream substrates such as NF-jB (West et al. 2002) . NF-jB is a nuclear transcription regulator with a specific motif for Bcl-2 transcription (Wang et al. 1996; Marsden et al. 2002) . Activation of p-Akt and the NF-jB/Bcl-2 pathway leads to inhibition of chemotherapy-induced apoptosis, which results in treatment resistance (Wang et al. 1996) . Our previous results confirmed that suppression of Akt and the NF-jB/Bcl-2 pathway by anticancer agents inhibited the growth and migration as well as induced the apoptosis and cell cycle arrest in human lung cancer A549 cells and breast cancer MDA-MB-231 cells (Wang et al. 2009 Zhang et al. 2012a, b) . In the present study, we indicated that the combination of VPA and HCCA significantly enhanced the inhibition of the proliferation and migration of LLC cells and the PI3K/Akt and Fig. 4 Effects of combination of VPA and HCCA on receptor protein expressions and phosphorylation of pEGFR/EGFR (a), pVEGFR2/VEGFR2 (b), and p-c-Met/c-Met (c) in LLC cells. The cells were treated with the indicated concentrations of VPA/ V and HCCA/C (V0.5/0.5 mM, V1/1 mM, C64/0.064 mM, C125/0.125 mM), and Ly (0.0125 mM). The protein expression and phosphorylation were analyzed by Western Blotting. The optical density (OD) of the band was normalized with respect to b-actin and is expressed as relative optical density (OD). The OD value of the bands shown as mean ± SD was relative to that of the control (0, the DMSO vehicle) designated as 100 %. Ly is the inhibitor of PI3K/Akt. For one experiment, 3 assays were carried out and only one set of gels is shown. Values with different letters (a-d) differ significantly (P \ 0.05). c/s and d/s represent the significant enhanced effects (P \ 0.05) compared with VPA or HCCA alone b NF-jB pathway by suppressing the phosphorylation and expression of Akt and the NF-jB expression and activating the apoptotic pathway of Bcl-2/Bax-mitochondrial-caspase-3 in LLC cells.
There has been the cross-talk in EGFR and c-Met pathways in cancer cells which is related to cancer cell proliferation and migration (Puri and Salgia 2008) . Suppression of EGFR, VEGFR, and c-Met led to the inhibition of cancer cell proliferation, migration and invasion (Morelli et al. 2006; Naumov et al. 2009; Wang et al. 2009; Colon et al. 2011; Zhang et al. 2012a, b) . Here we have confirmed that the combination of VPA and HCCA significantly enhanced the inhibition of the EGFR, VEGFR2 and c-Met receptors and their downstream targets such as Akt and NF-jB in LLC cells, which could contribute to the inhibition of LLC cell proliferation and migration.
In summary, our present results have demonstrated that the combination of VPA and HCCA significantly enhanced the inhibition of LLC cell proliferation and migration, and induced apoptosis and cell cycle arrest by targeting the EGFR, VEGFR2, and c-Met receptors-mediated signaling pathways of Akt and NF-jB in LLC cells. The combination of VPA and HCCA did not show significant inhibition of the growth of the normal mouse fibroblast NIH3T3 and the normal human umbilical endothelial vein cells (EA.hy926). All these findings suggest that the combination of VPA and HCCA may have the wide therapeutic and/or adjuvant therapeutic application in the treatment of lung cancer. The optical density (OD) of the band was normalized with respect to b-actin and is expressed as relative optical density (OD). The OD value of the bands shown as mean ± SD was relative to that of the control (0, the DMSO vehicle) designated as 100 %. Ly and Bay are the inhibitors of PI3K/Akt and NFjB, respectively. For one experiment, 3 assays were carried out and only one set of gels is shown. Values with different letters (a-f) differ significantly (P \ 0.05). d/s represents the significant enhanced effects (P \ 0.05) compared with VPA or HCCA alone
